Organovo Holdings, Inc. (ONVO)
| Market Cap | 3.51M |
| Revenue (ttm) | 122,000 |
| Net Income (ttm) | -12.39M |
| Shares Out | 1.45M |
| EPS (ttm) | -9.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,223 |
| Open | 2.260 |
| Previous Close | 2.370 |
| Day's Range | 2.250 - 2.490 |
| 52-Week Range | 2.140 - 21.960 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 19, 2025 |
About ONVO
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company’s lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a... [Read more]
Financial Performance
In 2023, Organovo Holdings's revenue was $109,000, a decrease of -70.54% compared to the previous year's $370,000. Losses were -$14.67 million, -15.00% less than in 2022.
Financial StatementsNews
Organovo Provides Business Update
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approach...
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approach...
Organovo Announces Reverse Stock Split
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel dise...
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugebo...
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approach...
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approache...
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas...
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas...
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Poster presented at DDW2024 demonstrating the potential of the Company's clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo will be presenting data on the Company's lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approache...
Organovo's fatty liver disease drug meets main goal in mid-stage study
Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease met the main goal in a mid-stage study, sending its shares up nearly 27% in premarket trade.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), in...
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory ...
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows:
Organovo Highlights FXR314 Combination Therapy Potential and Plan
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory ...
Organovo to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fi...
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstr...
Organovo Announces FXR Program
Lead Molecule Poised for Phase 2 in IBD Lead Molecule Poised for Phase 2 in IBD
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using n...